Virtual Library

Start Your Search

Y. Oh



Author of

  • +

    P2.03 - Poster Session/ Treatment of Locoregional Disease – NSCLC (ID 213)

    • Event: WCLC 2015
    • Type: Poster
    • Track: Treatment of Locoregional Disease – NSCLC
    • Presentations: 1
    • +

      P2.03-024 - PORT-First Strategy After Surgery in Patients with IIIA-N2 Non-Small Cell Lung Cancer (ID 332)

      09:30 - 09:30  |  Author(s): Y. Oh

      • Abstract
      • Slides

      Background:
      Postoperative radiotherapy (PORT) and postoperative chemotherapy (POCT) can be administered as adjuvant therapies in patients with non-small cell lung cancer (NSCLC). The purpose of this study was to investigate the clinical outcomes of the patients treated with PORT-first and following with/without POCT in stage IIIA-N2 NSCLC.

      Methods:
      From March 1997 to October 2012, 97 patients with stage IIIA-N2 NSCLC who received PORT-first and following with/without POCT were analysed. PORT began within 4-6 weeks after surgical resection, and was delivered using conventional fractionation (1.8 – 2.0 Gy / day) with total dose of 50.4 – 66 Gy. According to the patient’s comorbidity, platinum-based POCT was administered 3 – 4 weeks after completion of PORT. We analysed the outcomes and clinical factors affecting survivals.

      Results:
      Of 97 patients, 32 (33.0%) received POCT with median of 4 cycles (range, 2 – 6). The follow-up time ranged from 3 to 110 months (median, 24) and 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS) and overall survival (OS) were 50.6%, 42.2% and 36.6%. Five-year OS of patients treated with PORT and POCT was significantly higher than that of patients with PORT only (62.9% vs. 28.1%, p = 0.005), and no significant differences in LRRFS (58.9% vs. 47.5%, p = 0.935) and DMFS (52.3% vs. 38.8%, p = 0.541). In multivariate analysis, the significant prognostic factors affecting OS were the use of POCT (HR = 0.44, CI, 0.20 – 0.96, p = 0.039), type of surgery (pneumonectomy/lobectomy, HR = 1.83, CI, 1.01 – 3.35, p = 0.047) and the status of resection margin (positive/negative, HR = 3.20, CI, 1.14 – 8.99, p = 0.027).

      Conclusion:
      PORT-first strategy after surgery appears not to compromise the clinical outcomes in the treatment of stage IIIA-N2 NSCLC. The additional use of POCT showed improving effect on overall survival even in PORT-first setting.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.